The FDA approved rebisufligene etisparvovec-hopf (Fayuvi), the first disease-modifying gene therapy for pediatric Sanfilippo syndrome type A (MPS IIIA), marking a historic milestone for the disease.

The approval follows prior Orphan Drug, Fast Track, and Breakthrough Therapy designations, with Ultragenyx Pharmaceutical Inc. listed as the sponsor.

Ultragenyx expects Fayuvi to be available at specialized U.S. treatment centers within 30 to 60 days after clearance, enabling relatively rapid patient access.

Analysts weigh scenarios around revenue growth, profitability, and earnings as potential catalysts or risks for Ultragenyx’ stock performance in light of the new approval.

Ultragenyx CEO Emil Kakkis says that a major program failure would force cost reductions and strategic reprioritization to protect the company’s finances.

Patient advocacy groups celebrate the potential impact, highlighting shifts from bleak prognosis to an active treatment option and care plan.

Andelyn Biosciences is highlighted for its commercial-scale manufacturing using the AAV Curator Platform to produce Fayuvi.

The article notes it is behind a STAT+ paywall, with full details accessible to subscribers.

Safety profiles include common adverse events such as elevated liver enzymes, nausea, vomiting, fever, reduced appetite, and blood count changes, with serious risks like thrombotic microangiopathy and potential long-term tumor development due to vector integration.

Ultragenyx’ stock has faced substantial pressure over five years, raising questions about whether valuations reflect pipeline potential.

Financial disclosures show 2026 revenue guidance of roughly $730–760 million and about $436 million in cash as of mid-year, with potential PRV sales adding to the balance sheet.

Positive anecdotes emerge, such as Eliza treated early who reportedly has no seizures, no feeding tube, and active participation in school and activities.